NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the peer-reviewed publication of real-world evidence (RWE) demonstrating that first-line therapy with IBRANCE® (palbociclib) in ...

– Overall response rate of 42% and median progression-free survival of 11.1 months in heavily pre-treated patients (after 11 months median follow-up time and based on 48% of events) demonstrates the ...

On Thursday, Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) announced results from the Phase 3 PATINA trial. The trial demonstrated that the addition of IBRANCE (palbociclib) to ...

--Arvinas, Inc. and Pfizer Inc. today announced updated clinical data from a Phase 1 b combination cohort evaluating vepdegestrant, an investigational oral PROteolysis TArgeting Chimera estrogen ...

Richard Finn, of the Jonsson Comprehensive Cancer Center at UCLA and lead investigator of the PALOMA-1 study, explains the clinical implications of Ibrance's approval for hormone-positive, ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced positive top-line results from the Phase 3 PALOMA-2 trial for IBRANCE ® (palbociclib), an oral, first-in-class inhibitor of ...

Using proton pump inhibitors (PPIs) during treatment with palbociclib (Ibrance) capsules was linked to higher risks of progression and death among patients with breast cancer, according to a ...

At 125 mg palbociclib, two DLTs occurred (grade 3 anemia and grade 3 hypoxia), with no treatment-related deaths; one cerebral hemorrhage death was reported. The LITESPARK-024 trial showed a manageable ...

This release contains forward-looking information about vepdegestrant (ARV-471), IBRANCE® (palbociclib) and a global collaboration between Pfizer and Arvinas to develop and commercialize vepdegestrant ...

About IBRANCE® (palbociclib) 125 mg tablets and capsules IBRANCE is an oral inhibitor of CDKs 4 and 6, 1 which are key regulators of the cell cycle that trigger cellular progression. 2,3 In the U.S., ...